{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T04:42:11Z","timestamp":1792384931949,"version":"4.4.0"},"reference-count":41,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:00:00Z","timestamp":1792281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:00:00Z","timestamp":1792281600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Clin Neurosci"],"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>\n                      Prucalopride, a 5\u2010HT\n                      <jats:sub>4<\/jats:sub>\n                      receptor agonist, has shown potential for rapid anxiolytic and antidepressant effects in preclinical studies. This meta\u2010analysis aims to evaluate changes in anxiety and depressive symptoms after prucalopride treatment in chronically constipated adults.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A systematic search of PubMed, the Cochrane Central Register of Controlled Trials,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      , and reports from the Food and Drug Administration and European Medicines Agency was conducted from inception to 1 March 2026. Included studies were double\u2010blind randomized controlled trials originally designed to assess effectiveness in treating chronic constipation in adults. As preplanned, the primary endpoint was the change in anxiety and depressive symptoms. Standardized mean differences (SMDs) were pooled and analyzed using a random\u2010effects model. This study is registered with PROSPERO, number CRD42024602454.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Five randomized controlled trials, including 2,404 participants, were included. The meta\u2010analysis revealed a significantly greater improvement in anxiety and depressive symptoms derived from quality\u2010of\u2010life scores with prucalopride compared with placebo in the random\u2010effects model (SMD\u2009=\u2009\u22120.19, 95% confidence interval [CI] [\u22120.3117; \u22120.0707];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0019;\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200952%). Improvement in anxiety and depressive symptoms was associated with improvement of constipation, but not with the daily dose of prucalopride. All studies were rated as having some concerns for biais in selection of the reported result.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Prucalopride improves anxiety and depressive symptoms in chronic constipation. Further studies are needed to explore the potential repurposing of prucalopride for anxiety and depressive disorders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/pcn.70151","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T04:34:51Z","timestamp":1792384491000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of prucalopride on anxiety and depressive symptoms among constipated patients: A meta\u2010analysis of randomized controlled trials"],"prefix":"10.1111","author":[{"given":"Lucie","family":"Lebon","sequence":"first","affiliation":[{"name":"Service de psychiatrie de l'H\u00f4pital Bic\u00eatre Assistance Publique\u2010H\u00f4pitaux de Paris, H\u00f4pitaux Universitaires de l'Universit\u00e9 Paris\u2010Saclay  Kremlin\u2010Bic\u00eatre France"},{"name":"\u00c9quipe Moods, INSERM 1018, CESP (centre de recherche en \u00e9pid\u00e9miologie et sant\u00e9 des population), Facult\u00e9 de M\u00e9decine Universit\u00e9 Paris\u2010Saclay  Kremlin\u2010Bic\u00eatre France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0506-6688","authenticated-orcid":false,"given":"Denis J.","family":"David","sequence":"additional","affiliation":[{"name":"\u00c9quipe Moods, INSERM 1018, CESP (centre de recherche en \u00e9pid\u00e9miologie et sant\u00e9 des population), Facult\u00e9 de M\u00e9decine Universit\u00e9 Paris\u2010Saclay  Kremlin\u2010Bic\u00eatre France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4887-4025","authenticated-orcid":false,"given":"Matthieu","family":"Gasnier","sequence":"additional","affiliation":[{"name":"Service de psychiatrie de l'H\u00f4pital Bic\u00eatre Assistance Publique\u2010H\u00f4pitaux de Paris, H\u00f4pitaux Universitaires de l'Universit\u00e9 Paris\u2010Saclay  Kremlin\u2010Bic\u00eatre France"},{"name":"\u00c9quipe Moods, INSERM 1018, CESP (centre de recherche en \u00e9pid\u00e9miologie et sant\u00e9 des population), Facult\u00e9 de M\u00e9decine Universit\u00e9 Paris\u2010Saclay  Kremlin\u2010Bic\u00eatre France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9759-0833","authenticated-orcid":false,"given":"Indira","family":"Mendez\u2010David","sequence":"additional","affiliation":[{"name":"\u00c9quipe Moods, INSERM 1018, CESP (centre de recherche en \u00e9pid\u00e9miologie et sant\u00e9 des population), Facult\u00e9 de M\u00e9decine Universit\u00e9 Paris\u2010Saclay  Kremlin\u2010Bic\u00eatre France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3477-8956","authenticated-orcid":false,"given":"Laurent","family":"Becquemont","sequence":"additional","affiliation":[{"name":"\u00c9quipe Moods, INSERM 1018, CESP (centre de recherche en \u00e9pid\u00e9miologie et sant\u00e9 des population), Facult\u00e9 de M\u00e9decine Universit\u00e9 Paris\u2010Saclay  Kremlin\u2010Bic\u00eatre France"},{"name":"Centre de recherche clinique Paris\u2010Saclay, Assistance Publique\u2010H\u00f4pitaux de Paris H\u00f4pitaux Universitaires de l'Universit\u00e9 Paris\u2010Saclay, H\u00f4pital Bic\u00eatre  Kremlin\u2010Bic\u00eatre France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8534-224X","authenticated-orcid":false,"given":"C\u00e9line","family":"Verstuyft","sequence":"additional","affiliation":[{"name":"\u00c9quipe Moods, INSERM 1018, CESP (centre de recherche en \u00e9pid\u00e9miologie et sant\u00e9 des population), Facult\u00e9 de M\u00e9decine Universit\u00e9 Paris\u2010Saclay  Kremlin\u2010Bic\u00eatre France"},{"name":"D\u00e9partement de g\u00e9n\u00e9tique mol\u00e9culaire, Pharmacog\u00e9n\u00e9tique et Hormonologie de l'H\u00f4pital Bic\u00eatre, Assistance Publique\u2010H\u00f4pitaux de Paris H\u00f4pitaux Universitaires de l'Universit\u00e9 Paris\u2010Saclay, H\u00f4pital Bic\u00eatre  Kremlin\u2010Bic\u00eatre France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7763-4162","authenticated-orcid":false,"given":"Ren\u00e9","family":"Hen","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Columbia University  New York New York USA"},{"name":"Division of Systems Neuroscience New York State Psychiatric Institute  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9441-6079","authenticated-orcid":false,"given":"Emmanuelle","family":"Corruble","sequence":"additional","affiliation":[{"name":"Service de psychiatrie de l'H\u00f4pital Bic\u00eatre Assistance Publique\u2010H\u00f4pitaux de Paris, H\u00f4pitaux Universitaires de l'Universit\u00e9 Paris\u2010Saclay  Kremlin\u2010Bic\u00eatre France"},{"name":"\u00c9quipe Moods, INSERM 1018, CESP (centre de recherche en \u00e9pid\u00e9miologie et sant\u00e9 des population), Facult\u00e9 de M\u00e9decine Universit\u00e9 Paris\u2010Saclay  Kremlin\u2010Bic\u00eatre France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2549-4495","authenticated-orcid":false,"given":"Romain","family":"Colle","sequence":"additional","affiliation":[{"name":"Service de psychiatrie de l'H\u00f4pital Bic\u00eatre Assistance Publique\u2010H\u00f4pitaux de Paris, H\u00f4pitaux Universitaires de l'Universit\u00e9 Paris\u2010Saclay  Kremlin\u2010Bic\u00eatre France"},{"name":"\u00c9quipe Moods, INSERM 1018, CESP (centre de recherche en \u00e9pid\u00e9miologie et sant\u00e9 des population), Facult\u00e9 de M\u00e9decine Universit\u00e9 Paris\u2010Saclay  Kremlin\u2010Bic\u00eatre France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,18]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1476-5381.1977.tb07530.x","article-title":"Olfactory bulb ablation in the rat: Behavioural changes and their reversal by antidepressant drugs","volume":"60","author":"Riezen H","year":"1977","journal-title":"Br. J. Pharmacol."},{"key":"e_1_2_10_3_1","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.neuron.2009.04.017","article-title":"Neurogenesis\u2010dependent and \u2010independent effects of fluoxetine in an animal model of anxiety\/depression","volume":"62","author":"David DJ","year":"2009","journal-title":"Neuron"},{"key":"e_1_2_10_4_1","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1017\/S1461145711000782","article-title":"Modulation of neuroplasticity pathways and antidepressant\u2010like behavioural responses following the short\u2010term (3 and 7\u2009days) administration of the 5\u2010HT\u2084 receptor agonist RS67333","volume":"15","author":"Pascual\u2010Brazo J","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"e_1_2_10_5_1","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/npp.2013.332","article-title":"Rapid anxiolytic effects of a 5\u2010HT4 receptor agonist are mediated by a neurogenesis\u2010independent mechanism","volume":"39","author":"Mendez\u2010David I","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"e_1_2_10_6_1","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.biopsych.2019.08.009","article-title":"Rapid anxiolytic effects of RS67333, a serotonin type 4 receptor agonist, and aiazepam, a benzodiazepine, are mediated by projections from the prefrontal cortex to the dorsal raphe nucleus","volume":"87","author":"Faye C","year":"2020","journal-title":"Biol. Psychiatry"},{"key":"e_1_2_10_7_1","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.neuron.2007.07.041","article-title":"Serotonin4 (5\u2010HT4) receptor agonists are putative antidepressants with a rapid onset of action","volume":"55","author":"Lucas G","year":"2007","journal-title":"Neuron"},{"key":"e_1_2_10_8_1","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.encep.2021.09.001","article-title":"Reviving through human hippocampal newborn neurons","volume":"48","author":"Mendez\u2010David I","year":"2022","journal-title":"L'Encephale"},{"key":"e_1_2_10_9_1","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.biopsych.2004.12.023","article-title":"Frontocortical 5\u2010HT4 receptors exert positive feedback on serotonergic activity: Viral transfections, subacute and chronic treatments with 5\u2010HT4 agonists","volume":"57","author":"Lucas G","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"e_1_2_10_10_1","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1001\/jamapsychiatry.2022.4539","article-title":"Serotonin 4 receptor brain binding in major depressive disorder and association with memory dysfunction","volume":"80","author":"K\u00f6hler\u2010Forsberg K","year":"2023","journal-title":"JAMA Psychiatry"},{"key":"e_1_2_10_11_1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.biopsych.2024.08.009","article-title":"Effect of antidepressant treatment on 5\u2010HT4 receptor binding and associations with clinical outcomes and verbal memory in major depressive disorder","volume":"97","author":"Dam VH","year":"2025","journal-title":"Biol. Psychiatry"},{"key":"e_1_2_10_12_1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jpsychires.2024.11.043","article-title":"Changes in hippocampal volume, 5\u2010HT4 receptor binding, and verbal memory over the course of antidepressant treatment in major depressive disorder","volume":"181","author":"Jensen KHR","year":"2025","journal-title":"J. Psychiatr. Res."},{"key":"e_1_2_10_13_1","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1017\/S0033291720000604","article-title":"Translating the promise of 5HT 4 receptor agonists for the treatment of depression","volume":"51","author":"Murphy SE","year":"2021","journal-title":"Psychol. Med."},{"key":"e_1_2_10_14_1","doi-asserted-by":"crossref","unstructured":"De CatesAN GillespieAL ScaifeJet al.Effects on hippocampal activity following 5\u2010HT4receptor agonism in unmedicated patients with depression: The RESTAND study.medRxiv.2025.https:\/\/doi.org\/10.1101\/2025.08.29.25333049.","DOI":"10.1101\/2025.08.29.25333049"},{"key":"e_1_2_10_15_1","doi-asserted-by":"crossref","DOI":"10.1017\/S0033291726104450","article-title":"Pro\u2010cognitive effects of 5\u2010HT4 receptor agonism in individuals with remitted depression","volume":"56","author":"Cates AN","year":"2026","journal-title":"Psychol. Med."},{"key":"e_1_2_10_16_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1192\/bjp.2026.10664","article-title":"Early effects of a novel 5\u2010HT4R agonist (PF\u201004995274) and the SSRI citalopram on emotional cognition in unmedicated depression: RESTAND study","author":"Gillespie AL","year":"2026","journal-title":"Br. J. Psychiatry J. Ment. Sci."},{"key":"e_1_2_10_17_1","volume-title":"Summary of Product Characteristics. Prucalopride (ID: EMEA\/H\/C\/001012)","year":"2022"},{"key":"e_1_2_10_18_1","volume-title":"Summary of Product Characteristics. Prucalopride (ID: 4363584)","year":"2018"},{"key":"e_1_2_10_19_1","volume-title":"Assessment Report for Resolor\u00ae, International Non\u2010Proprietary Name: prucalopride","year":"2009"},{"key":"e_1_2_10_20_1","volume-title":"Prucalopride for the Treatment of Chronic Idiopathic Constipation","year":"2018"},{"key":"e_1_2_10_21_1","first-page":"1","article-title":"Association between a selective 5\u2010HT4 receptor agonist and incidence of major depressive disorder: Emulated target trial","volume":"7","author":"Cates AN","year":"2024","journal-title":"Br. J. Psychiatry J. Ment. Sci."},{"key":"e_1_2_10_22_1","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/S2468-1253(21)00111-4","article-title":"Global prevalence of functional constipation according to the Rome criteria: A systematic review and meta\u2010analysis","volume":"6","author":"Barberio B","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"e_1_2_10_23_1","unstructured":"World gastroenterology organisation global guidelines \u201cconstipation: A global perspective\u201d.2010. accessed on 12 October 2026. Available from URL:https:\/\/www.worldgastroenterology.org\/UserFiles\/file\/guidelines\/constipation-english-2010.pdf."},{"key":"e_1_2_10_24_1","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00406-014-0502-z","article-title":"Anxiety and depression comorbidities in irritable bowel syndrome (IBS): A systematic review and meta\u2010analysis","volume":"264","author":"Fond G","year":"2014","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"e_1_2_10_25_1","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/s12876-024-03454-x","article-title":"Can depression lead to chronic constipation, or does chronic constipation worsen depression? NHANES 2005\u20132010 and bidirectional mendelian randomization analyses","volume":"24","author":"He Z","year":"2024","journal-title":"BMC Gastroenterol."},{"key":"e_1_2_10_26_1","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1152435","article-title":"Association between constipation and major depression in adult Americans: Evidence from NHANES 2005\u20132010","volume":"14","author":"Shen X","year":"2023","journal-title":"Front. Psychiatry."},{"key":"e_1_2_10_27_1","unstructured":"Preferred reporting items for systematic reviews and meta\u2010analyses PRISMA.2020. accessed on 12 October 2026. Available from URL:http:\/\/www.prisma-statement.org\/."},{"key":"e_1_2_10_28_1","unstructured":"Cochrane handbook for systematic reviews of interventions. Version 6.4.2023. accessed on 12 October 2026. Available from URL:https:\/\/training.cochrane.org\/handbook."},{"key":"e_1_2_10_29_1","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/ajg.2015.115","article-title":"A randomized, double\u2010blind, placebo\u2010controlled, phase 3 trial to evaluate the efficacy, safety, and tolerability of prucalopride in men with chronic constipation","volume":"110","author":"Yiannakou Y","year":"2015","journal-title":"Am. J. Gastroenterol."},{"key":"e_1_2_10_30_1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1136\/gut.2008.162404","article-title":"Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives","volume":"58","author":"Tack J","year":"2009","journal-title":"Gut"},{"key":"e_1_2_10_31_1","article-title":"Prucalopride in the treatment of chronic constipation in patients from the Asia\u2010Pacific region: A randomized, double\u2010blind, placebo\u2010controlled study","volume":"24","author":"Ke M","year":"2012","journal-title":"Neurogastroenterol. Motil."},{"key":"e_1_2_10_32_1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1365-2036.2008.03884.x","article-title":"Clinical trial: The efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation \u2013 a 12\u2010week, randomized, double\u2010blind, placebo\u2010controlled study","volume":"29","author":"Quigley EMM","year":"2009","journal-title":"Aliment. Pharmacol. Ther."},{"key":"e_1_2_10_33_1","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/nmo.12553","article-title":"A randomized, double\u2010blind, placebo\u2010controlled trial to evaluate the efficacy, safety, and tolerability of long\u2010term treatment with prucalopride","volume":"27","author":"Piessevaux H","year":"2015","journal-title":"Neurogastroenterol. Motil."},{"key":"e_1_2_10_34_1","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.biopsych.2005.09.014","article-title":"Size of treatment effects and their importance to clinical research and practice","volume":"59","author":"Kraemer HC","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"e_1_2_10_35_1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta\u2010analyses","volume":"327","author":"Higgins JPT","year":"2003","journal-title":"BMJ"},{"key":"e_1_2_10_36_1","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1093\/ije\/dyn065","article-title":"Sensitivity of between\u2010study heterogeneity in meta\u2010analysis: Proposed metrics and empirical evaluation","volume":"37","author":"Patsopoulos NA","year":"2008","journal-title":"Int. J. Epidemiol."},{"key":"e_1_2_10_37_1","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen J","year":"1988"},{"key":"e_1_2_10_38_1","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1071\/HC16008","article-title":"Antidepressants for treatment of depression in primary care: A systematic review and meta\u2010analysis","volume":"8","author":"Arroll B","year":"2016","journal-title":"J. Prim. Health Care"},{"key":"e_1_2_10_39_1","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1046\/j.1365-2036.2002.01272.x","article-title":"Prucalopride, a systemic enterokinetic, for the treatment of constipation","volume":"16","author":"Emmanuel AV","year":"2002","journal-title":"Aliment. Pharmacol. Ther."},{"key":"e_1_2_10_40_1","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms9040723","article-title":"The microbiome\u2010gut\u2010Bbrain axis and resilience to developing anxiety or depression under stress","volume":"9","author":"Bear T","year":"2021","journal-title":"Microorganisms"},{"key":"e_1_2_10_41_1","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3945\/an.116.014407","article-title":"Mechanisms of action of probiotics and the gastrointestinal microbiota on gut motility and constipation","volume":"8","author":"Dimidi E","year":"2017","journal-title":"Adv. Nutr."},{"key":"e_1_2_10_42_1","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1007\/s11481-023-10085-8","article-title":"5\u2010HT4 receptor is protective for MPTP\u2010induced parkinson's disease mice via altering gastrointestinal motility or gut microbiota","volume":"18","author":"Cui C","year":"2023","journal-title":"J. Neuroimmune Pharmacol."}],"container-title":["Psychiatry and Clinical Neurosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pcn.70151","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/pcn.70151","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pcn.70151","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T04:35:08Z","timestamp":1792384508000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pcn.70151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,18]]},"references-count":41,"alternative-id":["10.1111\/pcn.70151"],"URL":"https:\/\/doi.org\/10.1111\/pcn.70151","archive":["Portico"],"relation":{},"ISSN":["1323-1316","1440-1819"],"issn-type":[{"value":"1323-1316","type":"print"},{"value":"1440-1819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,18]]},"assertion":[{"value":"2026-01-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"pcn.70151"}}